Global Pharma Lupin Spins Out Two Oncology Programs into Kaveri Therapeutics
Global pharmaceutical leader Lupin Limited announced the strategic spin-out of two key oncology programs, LNP7457 (PRMT5) and LNP8701 (SOS1), through its U.S.-based subsidiary, Lupin Inc., into a newly formed entity, Kaveri Therapeutics Inc.Kaveri is being established as an independent clinical-stage oncology company to advance these programs through global clinical trials. Under the terms of the agreement executed on July 20, 2026, Lupin Inc. provided seed funding and granted Kaveri an exclusive perpetual license for both programs.
In exchange for the licensing rights, Lupin Inc. received a substantial equity stake in Kaveri. The transaction valued the two oncology programs at USD 1.6 million, resulting in Lupin holding an 82.2% equity share in Kaveri.
Kaveri Therapeutics is focused on biomarker-driven clinical development and is dedicated to creating therapies for hard-to-treat cancers, particularly focusing on solid tumors such as lung, pancreatic, ovarian, and CNS-related cancers. The company will be led by Chief Executive Officer Kristi Jones and Chief Medical Officer Dr. Robert Pierce.
Both programs have shown encouraging clinical progress. LNP7457 (PRMT5) and LNP8701 (SOS1) both reported positive data at major scientific meetings, specifically the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively.
"We are proud to have pioneered these oncology assets and look forward to advancing them through Kaveri Therapeutics," said Vinita Gupta, Chief Executive Officer of Lupin. "The strength of these assets, combined with Kaveri's seasoned leadership team, positions us to accelerate the development of targeted oncology therapies with the goal of bringing meaningful innovation to patients."
Transaction Details Overview
A summary of the key elements of this strategic transaction is provided below:| Particulars | Detail |
|---|---|
| Target Entity | Kaveri Therapeutics, Inc. (Delaware, U.S.A.) |
| Programs Licensed | LNP7457 (PRMT5) and LNP8701 (SOS1) |
| Consideration Received by Lupin | 332,000 Common Shares in Kaveri |
| Equity Stake Acquired by Lupin | 82.2% |
| Value of Licensed Programs | USD 1.6 million |
| Completion Date | July 20, 2026 |
About Kaveri Therapeutics
Kaveri is committed to advancing differentiated small-molecule therapies targeting PRMT5 and SOS1/RAS pathway biology. The company's focus areas include lung, pancreatic, ovarian, and CNS relevant cancers, aiming to deliver cancer therapeutics for patients with limited treatment options.LUPIN Stock Price Movement
On Monday, Lupin Limited shares edged higher as the stock gained 1.78%, settling at ₹2478.50. The company's stock witnessed a trading volume of 688,779 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.